A Patient’s Plea for Justice
Kristen Ogden is a chronic pain patient advocate who has led the charge to protect her physician, Dr. Bockoff.
California Likely Fined $40M for Lapses in Prison Suicide Prevention
California could face more than $40 million in fines after it failed to improve suicide prevention measures in state prisons.
Abortion’s the Tiebreaker
Abortion might not be the main issue for voters, but it will be the issue that decides the swing states, ...
Legalities of Prison Healthcare
Healthcare in prison is notoriously lacking and clinical outcomes for those incarcerated are far worse than the national average.
Medical Crimes Against Humanity
By all accounts Dr. Bockoff was a kind and caring physician dedicated to improving the lives of his patients. Why ...
The Wolf That Killed Me as a Child
It has been more than 20 years since the start of these wars. Twenty years of silence. Twenty years of ...
Who Knows How to Spend Opioid Settlement Cash?
Addiction medicine doctor Stephen Loyd announced what he called “a game-changer” for state and local governments.
Execution of a Bad Man
To ensure the safety of the citizens of this great country, if there is any chance that a “bad man” ...
PT Water Therapy
Water therapy may seem like an unconventional choice for PT to some, but the benefits it provides are undeniable.
The Way Judges and Legislators Interact
Whatever high minded pretense we might have carried about the separations of power has long gone. Trump proved that easy ...
How Healthcare Fixes the Ballot
Health policy might not make headline news, but it subtlety affects how candidates posture to their voters.
Careful When Reporting on Psychedelics Research or Legislation
Despite the hype, optimism and legislation involving the potential of psychedelics, researchers warn that there's much we don't know.
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read morePopular
-
The IRA’s Drug Negotiation Mechanism Meets the Rebate Industrial Complex
-
Growth Hormone Secretagogues and the Longevity Trade-Off
-
GLP-1 Agonists Beyond Obesity: The Expanding Therapeutic and Optimization Frontier
-
The Second Reader That Never Sleeps: Large Language Models and Clinical Decision-Making
-
The Peptide Underground: Clinical Evidence, Compounding Markets, and the Optimization Economy
